| Name | 1,1,1,2,2-pentafluoro-7-phenylheptan-3-one |
|---|---|
| Synonyms |
1,1,1,2,2-Pentafluoro-7-phenyl-3-heptanone
3-Heptanone, 1,1,1,2,2-pentafluoro-7-phenyl- Phospholipase A FKGK 11 |
| Description | FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PLA2 |
| In Vitro | FKGK11 shows 99.4 ± 0.1% inhibition of GVIA iPLA2 and only 28 ± 1% for GV sPLA2 at 0.091 mole fraction[1]. FKGK11 reduces adhesion, migration, and invasion of EOC (epithelial ovarian cancer) cells[2]. |
| In Vivo | FKGK11 inhibits tumor development in the xenograft mouse model[2]. FKGK11 shows a significant increase in the number of macrophages and degenerating fibres with disrupted myelin sheaths in cPLA2 GIVA−/− mice and C57BL/6 mice[3]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 288.9±40.0 °C at 760 mmHg |
| Molecular Formula | C13H13F5O |
| Molecular Weight | 280.234 |
| Flash Point | 110.7±21.5 °C |
| Exact Mass | 280.088654 |
| PSA | 17.07000 |
| LogP | 5.40 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.434 |
| RIDADR | NONH for all modes of transport |
|---|